-
1
-
-
84857623883
-
Epidemiology of brain metastases
-
Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48-54.
-
(2012)
Curr Oncol Rep
, vol.14
, Issue.1
, pp. 48-54
-
-
Nayak, L.1
Lee, E.Q.2
Wen, P.Y.3
-
2
-
-
4344694453
-
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System
-
Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865-2872.
-
(2004)
J Clin Oncol.
, vol.22
, Issue.14
, pp. 2865-2872
-
-
Barnholtz-Sloan, J.S.1
Sloan, A.E.2
Davis, F.G.3
-
3
-
-
0018096512
-
Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival
-
Amer MH, Al-Sarraf M, Baker LH, et al. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42(2):660-668.
-
(1978)
Cancer
, vol.42
, Issue.2
, pp. 660-668
-
-
Amer, M.H.1
Al-Sarraf, M.2
Baker, L.H.3
-
4
-
-
0031975369
-
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
-
Sampson JH, Carter JH Jr., Friedman AH, et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88(1):11-20.
-
(1998)
J Neurosurg
, vol.88
, Issue.1
, pp. 11-20
-
-
Sampson, J.H.1
Carter, J.H.2
Friedman, A.H.3
-
5
-
-
0026718033
-
The role of radiation therapy in the treatment of brain metastases
-
Coia LR. The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys. 1992;23(1):229-238.
-
(1992)
Int J Radiat Oncol Biol Phys
, vol.23
, Issue.1
, pp. 229-238
-
-
Coia, L.R.1
-
6
-
-
38149075264
-
A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database
-
Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510-514.
-
(2008)
Int J Radiat Oncol Biol Phys
, vol.70
, Issue.2
, pp. 510-514
-
-
Sperduto, P.W.1
Berkey, B.2
Gaspar, L.E.3
-
7
-
-
77952567992
-
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients
-
Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655-661.
-
(2010)
Int J Radiat Oncol Biol Phys
, vol.77
, Issue.3
, pp. 655-661
-
-
Sperduto, P.W.1
Chao, S.T.2
Sneed, P.K.3
-
8
-
-
84916888200
-
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma
-
Marcus DM, Lowe M, Khan MK, et al. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am J Clin Oncol 2014;37(6):580-4.
-
(2014)
Am J Clin Oncol
, vol.37
, Issue.6
, pp. 580-584
-
-
Marcus, D.M.1
Lowe, M.2
Khan, M.K.3
-
9
-
-
79953799396
-
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma
-
Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117(8):1697-1703.
-
(2011)
Cancer
, vol.117
, Issue.8
, pp. 1697-1703
-
-
Eigentler, T.K.1
Figl, A.2
Krex, D.3
-
10
-
-
79955475531
-
Brain metastases as preventive and therapeutic targets
-
Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11(5): 352-363.
-
(2011)
Nat Rev Cancer
, vol.11
, Issue.5
, pp. 352-363
-
-
Steeg, P.S.1
Camphausen, K.A.2
Smith, Q.R.3
-
11
-
-
79951966253
-
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study
-
Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-141.
-
(2011)
J Clin Oncol
, vol.29
, Issue.2
, pp. 134-141
-
-
Kocher, M.1
Soffietti, R.2
Abacioglu, U.3
-
12
-
-
71249157772
-
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial
-
Chang EL,Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037-1044.
-
(2009)
Lancet Oncol
, vol.10
, Issue.11
, pp. 1037-1044
-
-
Chang, E.L.1
Wefel, J.S.2
Hess, K.R.3
-
13
-
-
33744954692
-
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial
-
Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483-2491.
-
(2006)
JAMA
, vol.295
, Issue.21
, pp. 2483-2491
-
-
Aoyama, H.1
Shirato, H.2
Tago, M.3
-
14
-
-
84911437178
-
Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: Whole brain radiotherapy versus stereotactic radiosurgery alone
-
Patel KR, Prabhu RS, Kandula S, et al. Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone. J Neurooncol. 2014;120(3): 657-63.
-
(2014)
J Neurooncol
, vol.120
, Issue.3
, pp. 657-663
-
-
Patel, K.R.1
Prabhu, R.S.2
Kandula, S.3
-
15
-
-
0027984157
-
Radiosensitivity of new and established human melanoma cell lines: Comparison of [3H]thymidine incorporation and soft agar clonogenic assays
-
Marshall ES, Matthews JH, Shaw JH, et al. Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. Eur J Cancer. 1994;30A(9):1370-1376.
-
(1994)
Eur J Cancer
, vol.30 A
, Issue.9
, pp. 1370-1376
-
-
Marshall, E.S.1
Matthews, J.H.2
Shaw, J.H.3
-
16
-
-
73149104401
-
The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma
-
Agrawal S, Kane JM 3rd, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009;115(24):5836-5844.
-
(2009)
Cancer
, vol.115
, Issue.24
, pp. 5836-5844
-
-
Agrawal, S.1
Kane, J.M.2
Guadagnolo, B.A.3
-
17
-
-
33750420947
-
Adjuvant radiotherapy for cutaneous melanoma: Comparing hypofractionation to conventional fractionation
-
Chang DT, Amdur RJ, Morris CG, et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys. 2006;66(4): 1051-1055.
-
(2006)
Int J Radiat Oncol Biol Phys
, vol.66
, Issue.4
, pp. 1051-1055
-
-
Chang, D.T.1
Amdur, R.J.2
Morris, C.G.3
-
18
-
-
79957541238
-
The evolving role of radiation therapy in the management of malignant melanoma
-
Khan N, Khan MK, Almasan A, et al. The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys. 2011;80(3):645-654.
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.80
, Issue.3
, pp. 645-654
-
-
Khan, N.1
Khan, M.K.2
Almasan, A.3
-
19
-
-
79952264449
-
Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article
-
Liew DN, Kano H, Kondziolka D, et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2011;114(3):769-779.
-
(2011)
J Neurosurg
, vol.114
, Issue.3
, pp. 769-779
-
-
Liew, D.N.1
Kano, H.2
Kondziolka, D.3
-
20
-
-
3042559645
-
Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases
-
Selek U, Chang EL, Hassenbusch SJ 3rd, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys. 2004;59(4): 1097-1106.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.59
, Issue.4
, pp. 1097-1106
-
-
Selek, U.1
Chang, E.L.2
Hassenbusch, S.J.3
-
21
-
-
58949097456
-
Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma
-
Powell JW, Chung CT, Shah HR, et al. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg. 2008;109(Suppl):122-128.
-
(2008)
J Neurosurg
, vol.109
, pp. 122-128
-
-
Powell, J.W.1
Chung, C.T.2
Shah, H.R.3
-
22
-
-
84872805876
-
Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases
-
Lwu S, Goetz P, Monsalves E, et al. Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases. Oncol Rep. 2013;29(2):407-412.
-
(2013)
Oncol Rep
, vol.29
, Issue.2
, pp. 407-412
-
-
Lwu, S.1
Goetz, P.2
Monsalves, E.3
-
23
-
-
84884903622
-
Challenges with the diagnosis and treatment of cerebral radiation necrosis
-
Chao ST, Ahluwalia MS, Barnett GH, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys. 2013;87(3):449-457.
-
(2013)
Int J Radiat Oncol Biol Phys
, vol.87
, Issue.3
, pp. 449-457
-
-
Chao, S.T.1
Ahluwalia, M.S.2
Barnett, G.H.3
-
24
-
-
0030060744
-
Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: Initial report of radiation therapy oncology group protocol (90-05)
-
Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). Int J Radiat Oncol Biol Phys. 1996;34(3): 647-654.
-
(1996)
Int J Radiat Oncol Biol Phys
, vol.34
, Issue.3
, pp. 647-654
-
-
Shaw, E.1
Scott, C.2
Souhami, L.3
-
25
-
-
79955876849
-
Stereotactic radiosurgery for brain metastases: Analysis of outcome and risk of brain radionecrosis
-
Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011;6:48.
-
(2011)
Radiat Oncol
, vol.6
, pp. 48
-
-
Minniti, G.1
Clarke, E.2
Lanzetta, G.3
-
26
-
-
84878649850
-
Hypofractionated radiosurgery for intact or resected brain metastases: Defining the optimal dose and fractionation
-
Eaton BR, Gebhardt B, Prabhu R, et al. Hypofractionated radiosurgery for intact or resected brain metastases: defining the optimal dose and fractionation. Radiat Oncol. 2013;8:135.
-
(2013)
Radiat Oncol
, vol.8
, pp. 135
-
-
Eaton, B.R.1
Gebhardt, B.2
Prabhu, R.3
-
27
-
-
0034614637
-
The hallmarks of cancer
-
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
-
(2000)
Cell
, vol.100
, Issue.1
, pp. 57-70
-
-
Hanahan, D.1
Weinberg, R.A.2
-
28
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
-
(2011)
Cell
, vol.144
, Issue.5
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
29
-
-
55949083407
-
Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment
-
Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26(32):5275-5283.
-
(2008)
J Clin Oncol
, vol.26
, Issue.32
, pp. 5275-5283
-
-
Fong, L.1
Small, E.J.2
-
30
-
-
0029947568
-
Enhancement of antitumor immunity by CTLA-4 blockade
-
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736.
-
(1996)
Science
, vol.271
, Issue.5256
, pp. 1734-1736
-
-
Leach, D.R.1
Krummel, M.F.2
Allison, J.P.3
-
31
-
-
0033592924
-
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
-
Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA. 1999;96(26): 15074-15079.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, Issue.26
, pp. 15074-15079
-
-
Kwon, E.D.1
Foster, B.A.2
Hurwitz, A.A.3
-
32
-
-
77955256254
-
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study
-
O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21(8):1712-1717.
-
(2010)
Ann Oncol
, vol.21
, Issue.8
, pp. 1712-1717
-
-
O'Day, S.J.1
Maio, M.2
Chiarion-Sileni, V.3
-
33
-
-
69949095926
-
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
-
Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17): 5591-5598.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.17
, pp. 5591-5598
-
-
Weber, J.1
Thompson, J.A.2
Hamid, O.3
-
34
-
-
75249100054
-
Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study
-
Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155-164.
-
(2010)
Lancet Oncol
, vol.11
, Issue.2
, pp. 155-164
-
-
Wolchok, J.D.1
Neyns, B.2
Linette, G.3
-
35
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.23
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
-
36
-
-
84880511594
-
Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma
-
Wolchok JD, Hodi FS, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291:1-13.
-
(2013)
Ann N y Acad Sci
, vol.1291
, pp. 1-13
-
-
Wolchok, J.D.1
Hodi, F.S.2
Weber, J.S.3
-
37
-
-
33748743268
-
CNS immune privilege: Hiding in plain sight
-
Carson MJ, Doose JM, Melchior B, et al. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48-65.
-
(2006)
Immunol Rev
, vol.213
, pp. 48-65
-
-
Carson, M.J.1
Doose, J.M.2
Melchior, B.3
-
38
-
-
84873323242
-
Role of the systemic immune system in brain metastasis
-
Hamilton A, Sibson NR. Role of the systemic immune system in brain metastasis. Mol Cell Neurosci. 2013;53:42-51.
-
(2013)
Mol Cell Neurosci
, vol.53
, pp. 42-51
-
-
Hamilton, A.1
Sibson, N.R.2
-
39
-
-
84928898198
-
Unsanctifying the sanctuary: Challenges and opportunities with brain metastases
-
Puhalla S, ElmquistW, Freyer D, et al. Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol. 2015;17(5):639-651.
-
(2015)
Neuro Oncol
, vol.17
, Issue.5
, pp. 639-651
-
-
Puhalla, S.1
Elmquistw Freyer, D.2
-
40
-
-
84880573419
-
Pathologic and gene expression features of metastatic melanomas to the brain
-
Hamilton R, Krauze M, Romkes M, et al. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer. 2013;119(15):2737-2746.
-
(2013)
Cancer
, vol.119
, Issue.15
, pp. 2737-2746
-
-
Hamilton, R.1
Krauze, M.2
Romkes, M.3
-
41
-
-
51149116051
-
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
-
Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008; 5(9):557-561.
-
(2008)
Nat Clin Pract Oncol
, vol.5
, Issue.9
, pp. 557-561
-
-
Hodi, F.S.1
Oble, D.A.2
Drappatz, J.3
-
42
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
43
-
-
84858440498
-
Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: Subgroup analyses from a phase III trial [abstract]
-
Lebbe C, McDermott DF, Robert C, et al. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial [abstract]. Ann Oncol. 2010;21(suppl 8):401.
-
(2010)
Ann Oncol
, vol.21
, pp. 401
-
-
Lebbe, C.1
McDermott, D.F.2
Robert, C.3
-
44
-
-
84860446616
-
Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial
-
Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465.
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 459-465
-
-
Margolin, K.1
Ernstoff, M.S.2
Hamid, O.3
-
45
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
46
-
-
84865567547
-
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-arm phase 2 trial
-
Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012; 13(9):879-886.
-
(2012)
Lancet Oncol
, vol.13
, Issue.9
, pp. 879-886
-
-
Di Giacomo, A.M.1
Ascierto, P.A.2
Pilla, L.3
-
47
-
-
80955130103
-
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: Retrospective analysis of data from a phase 2 trial
-
Weber JS, Amin A, Minor D, et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 2011;21(6):530-534.
-
(2011)
Melanoma Res
, vol.21
, Issue.6
, pp. 530-534
-
-
Weber, J.S.1
Amin, A.2
Minor, D.3
-
48
-
-
84901633374
-
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
-
Queirolo P, Spagnolo F, Ascierto PA, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol. 2014;118(1):109-16.
-
(2014)
J Neurooncol
, vol.118
, Issue.1
, pp. 109-116
-
-
Queirolo, P.1
Spagnolo, F.2
Ascierto, P.A.3
-
49
-
-
84864559660
-
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival
-
Knisely JP, Yu JB, Flanigan J, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117(2):227-233.
-
(2012)
J Neurosurg
, vol.117
, Issue.2
, pp. 227-233
-
-
Knisely, J.P.1
Yu, J.B.2
Flanigan, J.3
-
50
-
-
84877043331
-
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
-
Mathew M, Tam M, Ott PA, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013;23(3):191-195.
-
(2013)
Melanoma Res
, vol.23
, Issue.3
, pp. 191-195
-
-
Mathew, M.1
Tam, M.2
Ott, P.A.3
-
51
-
-
84904216679
-
Ipilimumab and radiation therapy for melanoma brain metastases
-
Silk AW, Bassetti MF, West BT, et al. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013; 2(6):899-906.
-
(2013)
Cancer Med
, vol.2
, Issue.6
, pp. 899-906
-
-
Silk, A.W.1
Bassetti, M.F.2
West, B.T.3
-
52
-
-
84921938937
-
Ipilimumab and whole brain radiation therapy for melanoma brain metastases
-
Gerber NK, Young RJ, Barker CA, et al. Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol. 2015;121(1):159-165.
-
(2015)
J Neurooncol
, vol.121
, Issue.1
, pp. 159-165
-
-
Gerber, N.K.1
Young, R.J.2
Barker, C.A.3
-
53
-
-
84928938600
-
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment
-
Kiess AP,Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368-75.
-
(2015)
Int J Radiat Oncol Biol Phys
, vol.92
, Issue.2
, pp. 368-375
-
-
Kiess, A.P.1
Wolchok, J.D.2
Barker, C.A.3
-
54
-
-
84867580941
-
Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies
-
Du Four S, Wilgenhof S, Duerinck J, et al. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer 2012;48(16):3045-3051.
-
(2012)
Eur J Cancer
, vol.48
, Issue.16
, pp. 3045-3051
-
-
Du Four, S.1
Wilgenhof, S.2
Duerinck, J.3
-
55
-
-
84953850731
-
Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients
-
Du Four S, Hong A, Chan M, et al. Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients. Case Rep Oncol Med. 2014;2014:417-913.
-
(2014)
Case Rep Oncol Med
, vol.2014
, pp. 417-913
-
-
Du Four, S.1
Hong, A.2
Chan, M.3
-
56
-
-
84952023257
-
Ipilimumab and Stereotactic Radiosurgery vs. Stereotactic Radiosurgery alone for Newly Diagnosed Melanoma Brain Metastases
-
In Press
-
Patel KR, Oliver DE, Rizzo M, et al. Ipilimumab and Stereotactic Radiosurgery vs. Stereotactic Radiosurgery alone for Newly Diagnosed Melanoma Brain Metastases. Am J Clin Oncol. 2015; In Press.
-
(2015)
Am J Clin Oncol
-
-
Patel, K.R.1
Oliver, D.E.2
Rizzo, M.3
-
57
-
-
0029243776
-
The effects of corticosteroids on lymphocyte recirculation in humans: Analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration
-
Sackstein R, Borenstein M. The effects of corticosteroids on lymphocyte recirculation in humans: analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration. J Investig Med. 1995;43(1): 68-77.
-
(1995)
J Investig Med
, vol.43
, Issue.1
, pp. 68-77
-
-
Sackstein, R.1
Borenstein, M.2
-
58
-
-
84891849910
-
Antitumor immune responses induced by ionizing irradiation and further immune stimulation
-
Frey B, Rubner Y, Kulzer L, et al. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol, Immunother: 2014;63(1):29-36.
-
(2014)
Cancer Immunol Immunother
, vol.63
, Issue.1
, pp. 29-36
-
-
Frey, B.1
Rubner, Y.2
Kulzer, L.3
-
59
-
-
70149113060
-
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment
-
Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589-595.
-
(2009)
Blood
, vol.114
, Issue.3
, pp. 589-595
-
-
Lee, Y.1
Auh, S.L.2
Wang, Y.3
-
60
-
-
33646704729
-
Radiation modulates the peptide repertoire, enhances MHC class i expression, and induces successful antitumor immunotherapy
-
Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006; 203(5):1259-1271.
-
(2006)
J Exp Med
, vol.203
, Issue.5
, pp. 1259-1271
-
-
Reits, E.A.1
Hodge, J.W.2
Herberts, C.A.3
-
61
-
-
1242315588
-
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
-
Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862-870.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, Issue.3
, pp. 862-870
-
-
Demaria, S.1
Ng, B.2
Devitt, M.L.3
-
62
-
-
34248545443
-
Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation
-
Tsai MH, Cook JA, Chandramouli GV, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res. 2007;67(8): 3845-3852.
-
(2007)
Cancer Res
, vol.67
, Issue.8
, pp. 3845-3852
-
-
Tsai, M.H.1
Cook, J.A.2
Chandramouli, G.V.3
-
63
-
-
0842266786
-
Interferon-gamma: An overview of signals, mechanisms and functions
-
Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163-189.
-
(2004)
J Leukoc Biol
, vol.75
, Issue.2
, pp. 163-189
-
-
Schroder, K.1
Hertzog, P.J.2
Ravasi, T.3
-
64
-
-
84857815877
-
Immunologic correlates of the abscopal effect in a patient with melanoma
-
Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-931.
-
(2012)
N Engl J Med
, vol.366
, Issue.10
, pp. 925-931
-
-
Postow, M.A.1
Callahan, M.K.2
Barker, C.A.3
-
65
-
-
84943368706
-
Comparing radiation therapy and ipilimumab to Iipilimumab alone in metastatic melanoma patients [abstract 247]
-
April 19 Philadelphia
-
Patel KR, Liu YL, Shoukat S. Comparing radiation therapy and ipilimumab to Iipilimumab alone in metastatic melanoma patients [abstract 247]. In: American Association of Cancer Research Annual Meeting; April 19, 2015; Philadelphia.
-
(2015)
American Association of Cancer Research Annual Meeting
-
-
Patel, K.R.1
Liu, Y.L.2
Shoukat, S.3
-
66
-
-
84888805558
-
Vemurafenib and ipilimumab: New agents for metastatic melanoma
-
Banaszynski M, Kolesar JM. Vemurafenib and ipilimumab: new agents for metastatic melanoma. Am J Health Syst Pharm. 2013;70(14):1205-1210.
-
(2013)
Am J Health Syst Pharm
, vol.70
, Issue.14
, pp. 1205-1210
-
-
Banaszynski, M.1
Kolesar, J.M.2
-
67
-
-
84888109114
-
Ipilimumab and vemurafenib: Two different routes for targeting melanoma
-
Burgeiro A, Mollinedo F, Oliveira PJ. Ipilimumab and vemurafenib: two different routes for targeting melanoma. Curr Cancer Drug Targets. 2013;13(8):879-94.
-
(2013)
Curr Cancer Drug Targets
, vol.13
, Issue.8
, pp. 879-894
-
-
Burgeiro, A.1
Mollinedo, F.2
Oliveira, P.J.3
-
68
-
-
84878875962
-
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
-
Di Giacomo AM, Calabro L, Danielli R, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother. 2013;62(6):1021-1028.
-
(2013)
Cancer Immunol Immunother
, vol.62
, Issue.6
, pp. 1021-1028
-
-
Di Giacomo, A.M.1
Calabro, L.2
Danielli, R.3
|